Peptides for bone mass, blood pressure, and IGF-1: what the evidence says

What did @fix.your.sh1t actually say?

Straightforwardly: nothing. The transcript for this 621,000-view video is not a health explanation. It is a song, or song fragments, with lyrics like "I'm so lucky lucky" and "Starving in blueends." There are no spoken claims about peptides, bone mass, blood pressure, debloating, or IGF-1 signaling. There is nothing to quote directly because nothing medically relevant was said.

The hashtags, though, tell a different story. The creator tagged this video with #bonemass, #bp, #debloat, #looks, and #igf1signaling. Those tags are doing implied marketing work that the audio does not support. Viewers searching peptide content will find this video. Many will assume the visual content explains something about those topics. That gap between implied promise and actual content is worth examining on its own terms.

Does the science back this up?

There is no claim here to evaluate against the science. But since the hashtags gesture at specific physiological concepts, it is worth briefly grounding what those terms actually mean in a clinical context.

IGF-1 (insulin-like growth factor 1) signaling is a legitimate area of peptide research. Growth hormone secretagogues like ipamorelin and CJC-1295 do stimulate pituitary GH release, which downstream raises IGF-1. A 2019 review by Sigalos and Pastuszak in Sexual Medicine Reviews summarized that these compounds show measurable effects on body composition in small studies, but long-term safety data in healthy adults remains thin. "Bone mass" effects tied to GH axis peptides are real in deficiency states, less clear in optimization contexts. Blood pressure effects of most peptides in this category are not well established. BPC-157 has shown some vasomodulatory properties in animal models (Sikiric et al., 2018, Current Pharmaceutical Design), but human data is essentially nonexistent.

What did they get wrong (or right)?

Nothing was said, so nothing was technically wrong or right in the audio. That is not a defense of the content. It is actually the problem.

Using hashtags like #igf1signaling on a video with no actual information creates a kind of implied credibility. Viewers may assume the visual component, which we cannot evaluate here, delivered real guidance. If someone watches this and walks away thinking they understand IGF-1 signaling well enough to pursue peptide therapy, that is a meaningful risk. Peptides like MK-677, semax, or GHK-Cu are not toys. MK-677 raises cortisol and prolactin in some users (Nass et al., 2008, Journal of Clinical Endocrinology and Metabolism). Uninformed use has real consequences.

The creator does not get credit for accuracy here. They also do not get dinged for specific misinformation. What they do deserve scrutiny for is participating in a content format that implies expertise without delivering it.

What should you actually know?

If you landed on this video because you are researching peptide therapy for bone density, blood pressure, or body composition, here is what the actual evidence supports.

• Growth hormone secretagogues have shown modest improvements in lean mass and fat reduction in adults with GH deficiency. Evidence in healthy adults is weaker and shorter-term.
• IGF-1 elevation via peptides is measurable, but higher IGF-1 is not automatically better. Elevated IGF-1 has been associated with increased cancer risk in some epidemiological data (Renehan et al., 2004, Lancet).
• BPC-157 has a compelling preclinical profile for gut healing and tendon repair. Zero completed human RCTs exist as of 2024.
• No peptide in the category covered by this platform's content has FDA approval for general wellness or aesthetics. Compounded versions are not equivalent to hypothetical approved versions.
• Any provider who gives you a peptide protocol without reviewing your IGF-1 baseline, metabolic panel, and personal history is skipping steps that matter.

The hashtag #debloat attached to peptide content is a particular flag. Bloating has dozens of causes. Peptides are not a first-line or evidence-supported intervention for most of them.